JP2024509501A5 - - Google Patents
Info
- Publication number
- JP2024509501A5 JP2024509501A5 JP2023544261A JP2023544261A JP2024509501A5 JP 2024509501 A5 JP2024509501 A5 JP 2024509501A5 JP 2023544261 A JP2023544261 A JP 2023544261A JP 2023544261 A JP2023544261 A JP 2023544261A JP 2024509501 A5 JP2024509501 A5 JP 2024509501A5
- Authority
- JP
- Japan
- Prior art keywords
- hhla2
- seq
- amino acid
- acid sequence
- binder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163142832P | 2021-01-28 | 2021-01-28 | |
| US63/142,832 | 2021-01-28 | ||
| PCT/US2022/014423 WO2022165258A1 (en) | 2021-01-28 | 2022-01-28 | Hhla2 binding agents with novel activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024509501A JP2024509501A (ja) | 2024-03-04 |
| JP2024509501A5 true JP2024509501A5 (enExample) | 2025-02-04 |
Family
ID=82652818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023544261A Pending JP2024509501A (ja) | 2021-01-28 | 2022-01-28 | 新規活性を持つｈｈｌａ２結合剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250270323A1 (enExample) |
| EP (1) | EP4284431A4 (enExample) |
| JP (1) | JP2024509501A (enExample) |
| KR (1) | KR20230135637A (enExample) |
| CN (1) | CN116981476A (enExample) |
| AU (1) | AU2022214939A1 (enExample) |
| BR (1) | BR112023014826A2 (enExample) |
| CA (1) | CA3207494A1 (enExample) |
| IL (1) | IL304584A (enExample) |
| MX (1) | MX2023008182A (enExample) |
| WO (1) | WO2022165258A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025054560A2 (en) * | 2023-09-08 | 2025-03-13 | Nextpoint Therapeutics, Inc. | Antibody-drug conjugates |
| CN119841949A (zh) * | 2023-10-17 | 2025-04-18 | 科辉智药(深圳)新药研究中心有限公司 | 一种抗人hhla2的纳米抗体及其应用 |
| CN121005781A (zh) * | 2024-05-24 | 2025-11-25 | 合肥天港免疫药物有限公司 | 高亲和力b7h7抗体或其抗原结合片段及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015167948A1 (en) * | 2014-04-30 | 2015-11-05 | Albert Einstein College Of Medicine Of Yeshiva University | Tmigd2 and its derivatives as blockers or binders of cancer-expressed hhla2 for immunotherapies |
| AU2018296067B2 (en) * | 2017-07-06 | 2021-06-10 | Merus B.V. | Binding molecules that modulate a biological activity expressed by a cell |
| JP7429192B2 (ja) * | 2018-04-06 | 2024-02-07 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｈｈｌａ２受容体としてのｋｉｒ３ｄｌ３、抗ｈｈｌａ２抗体、およびその使用 |
-
2022
- 2022-01-28 MX MX2023008182A patent/MX2023008182A/es unknown
- 2022-01-28 CN CN202280012137.1A patent/CN116981476A/zh active Pending
- 2022-01-28 EP EP22746752.9A patent/EP4284431A4/en active Pending
- 2022-01-28 JP JP2023544261A patent/JP2024509501A/ja active Pending
- 2022-01-28 KR KR1020237028708A patent/KR20230135637A/ko active Pending
- 2022-01-28 CA CA3207494A patent/CA3207494A1/en active Pending
- 2022-01-28 US US18/263,313 patent/US20250270323A1/en active Pending
- 2022-01-28 BR BR112023014826A patent/BR112023014826A2/pt unknown
- 2022-01-28 AU AU2022214939A patent/AU2022214939A1/en active Pending
- 2022-01-28 WO PCT/US2022/014423 patent/WO2022165258A1/en not_active Ceased
-
2023
- 2023-07-19 IL IL304584A patent/IL304584A/en unknown